Navigation Links
CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
Date:3/31/2008

Triggers $22-million Tranche of Venture Capital Funding

SUNNYVALE, Calif., March 31 /PRNewswire/ -- CardioMind, Inc., a developer of stents for small, difficult-to-treat blood vessels, announced today that it has begun a First-in-Human clinical trial of its drug-eluting stent. The CARE II trial, as it is called, began in February at St. Vincent's Hospital in Melbourne, Australia, and, so far, has led to successful implantations in 12 patients.

With a .014-inch crossing profile, the CardioMind stent, known as the Sparrow(TM) Drug-Eluting Coronary Stent System, is 70% smaller in diameter than any other currently-approved stent. It targets treatment of blood vessels smaller than 2.75 mm in diameter, which currently constitute nearly 40% of all stent implants. The tightness of fit of conventional stents, as well as their inflexibility and the forces delivered by balloon expansion, however, may contribute to increased vessel trauma, which in turn leads to less favorable long term results. Beyond the range of current stenting practice, moreover, the CardioMind stent may also find use in vessels smaller than 2.25 mm and thus expand by up to 20% the worldwide market for stents, now over $4-billion annually.

"We view the Sparrow system as a platform technology for a gentler stent delivery system that will both improve safety and efficacy for currently performed procedures and also extend treatment to new areas of the coronary, neurovascular and peripheral artery system," says Charles Maroney, President and CEO of CardioMind.

How the CardioMind Stent Works

The unique design of the CardioMind Sparrow stent permits it to travel within the guidewire lumen to the site of the lesion. There the cardiologist releases the stent and allows it to self-expand to the vessel wall. By contrast, conventional balloon-expandable stents travel over guidewires to the lesion, and thus, by their very design, occupy more volume. The Sparrow stent also offers more flexibility than current stents, making it especially adaptable to treatment of the small, tortuous blood vessels often associated with diabetes.

To coat the Sparrow stent, CardioMind has licensed the rights to the SynBiosys(TM) biodegradable polymer system from SurModics, Inc. (Nasdaq: SRDX). "The SynBiosys polymer allows the Sparrow stent to gradually return to a bare metal state, where we as an industry have 15 years of data showing no increase in late stent thrombosis," says Maroney.

Clinical Trials

The multi-site CARE II study, which will eventually enroll 220 patients, is a randomized trial of three different stents -- both bare-metal and drug-eluting versions of the Sparrow, plus a competitive stent.

According to Dr. Robert Whitbourn, associate professor and director of the Cardiovascular Research Center at St. Vincent's Hospital and one of the study's lead investigators: "Thus far, the first cases in this study are very encouraging. All our implanted patients are doing well, and I am impressed with the overall deliverability and performance of this new stent delivery system." Dr. Whitbourn expects to report first full follow-up results in eight months.

Overall, says Dr. Whitbourn, "The CardioMind Sparrow System represents a promising technology in interventional cardiology. The concept of a true guidewire-delivered stent opens up the possibilities of stenting in small vessels, branch vessels and other difficult-to-access vessels. It could, thus, expand the types of lesions in coronary artery disease that can be treated in more difficult patient populations."

Venture Funding

By reaching its First-in-Human milestone, CardioMind triggered the second tranche closing of a $33-million venture capital round raised in June 2007. That round, CardioMind's third since it was founded in 2003, included an initial $11-million for research and development and the just-released $22-million for completion of the CARE II Study and further development. Co-leaders of the round were SV Life Sciences and De Novo Ventures, with additional funding coming from existing investors InterWest Partners, Latterell Venture Partners, Morgenthaler Ventures, and Onset Ventures.

About CardioMind

CardioMind is a developer of a unique stent delivery platform that allows interventionalists to treat very small blood vessels of 2.75 mm-diameter and less. Such vessels, often tortuous, have proven especially vulnerable to injury from conventional stent delivery systems. The small crossing profile and flexibility of the CardioMind platform promise to increase both stent safety and efficacy in such vessels and to extend the range of vessels in which stents can be deployed throughout the coronary, neurovascular and peripheral artery systems.


'/>"/>
SOURCE CardioMind, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
2. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
3. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
4. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
5. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
6. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
7. Premier Micronutrient Launches Supplement for Hearing Health
8. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
9. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
10. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
11. PositiveFriends.com Launches STD Social Networking Site Balancing Dating with Online Support Features
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... , July 10, 2017  BDI Group ... and patient support services organization serving specialty pharmacies, ... the launch of four significant, value-added member programs ... insights, better manage reimbursement and improve access and ... factor therapies. ...
(Date:7/10/2017)... N.C. , July 10, 2017 Locus ... Convertible Note to support the development of CRISPR-Cas3 antimicrobial ... Holdings Limited, a leading Chinese Internet services provider, and ... will advance multiple infectious disease product programs targeting antibiotic ... Founded by Dr. Rodolphe Barrangou ...
(Date:7/5/2017)... July 5, 2017 Wolfmet 3D  printed tungsten collimator manufactured ... physics and manufacturing combine to progress molecular radiotherapy imaging. ... systems are unable to accurately quantify the radiation absorbed by ... regarding the success of this radiotherapy treatment has been available ... ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... The Ellis Agency, an eastern Georgie ... Foundation in a community wide charity event with the goal of bringing in support ... local woman who lives with epilepsy, recently launched a charity campaign of her own ...
(Date:7/21/2017)... ... July 21, 2017 , ... Thomas Jefferson University , ... was awarded a $300,000 grant from The Pew Center for Arts & Heritage ... and the recognition of one’s own limits among health professions students. , ...
(Date:7/21/2017)... NJ (PRWEB) , ... July 21, 2017 , ... ... has received a $5,000 grant from the C. R. Bard Foundation, ... Day Center at Somerset Hills , a service available through the nonprofit home ...
(Date:7/21/2017)... CANADA (PRWEB) , ... July 21, 2017 , ... ... 80% follow-up at 10 years, researchers from the Multicenter Orthopaedics Outcome Network (MOON) ... of life a decade after surgery, though activity levels decline over time. The ...
(Date:7/20/2017)... MA (PRWEB) , ... July 20, 2017 , ... ... form of blood and bone marrow cancer that progresses rapidly without treatment. Newly ... recommended to reduce the chance of reoccurrence and relapse. With such a ...
Breaking Medicine News(10 mins):